Overall, these results demonstrate that inhibition of LOXL2 using our novel active-site neutralizing mAb reduces the amount of fibrotic collagenous matrix in liver fibrosis and modifies its arrangement and assembly. This evidence concerns the gene LOXL2 and Hepatic fibrosis.